Last reviewed · How we verify
SK-1403
SK-1403 is a small molecule drug that targets the molecular target.
SK-1403 is a small molecule drug that targets the molecular target. Used for Unknown.
At a glance
| Generic name | SK-1403 |
|---|---|
| Sponsor | Sanwa Kagaku Kenkyusho Co., Ltd. |
| Drug class | Unknown |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Unknown |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- Unknown
Common side effects
- Unknown
Key clinical trials
- SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis (PHASE3)
- Phase 3 Study of SK-1403 (PHASE3)
- Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SK-1403 CI brief — competitive landscape report
- SK-1403 updates RSS · CI watch RSS
- Sanwa Kagaku Kenkyusho Co., Ltd. portfolio CI